Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Failure of acetazolamide to decrease intraocular pressure in patients with carbonic anhydrase II deficiency.

T Krupin, W S Sly, M P Whyte

    American Journal of Ophthalmology
    |April 15, 1985
    PubMed
    Summary

    Acetazolamide, a carbonic anhydrase inhibitor, effectively lowers intraocular pressure in healthy individuals. However, it does not reduce eye pressure in patients with carbonic anhydrase II deficiency.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Periodontal Defects in the A116T Knock-in Murine Model of Odontohypophosphatasia.

    Journal of dental research·2015
    Same author

    Enzyme replacement therapy prevents dental defects in a model of hypophosphatasia.

    Journal of dental research·2011
    Same author

    Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

    The Journal of clinical endocrinology and metabolism·2010
    Same author

    Selective loss of pattern discrimination in early glaucoma.

    Applied optics·2010
    Same author

    Influence of serial practice on Farnsworth-Munsell 100-hue scores: the learning effect.

    Applied optics·2010
    Same author

    Pigmentary glaucoma: facts versus fiction.

    Journal of glaucoma·2009

    Area of Science:

    • Ophthalmology
    • Biochemistry
    • Genetics

    Background:

    • Carbonic anhydrase II (CA-II) is crucial for various physiological processes.
    • CA-II deficiency is linked to rare genetic syndromes like osteopetrosis, renal tubular acidosis, and cerebral calcification.
    • The role of CA-II in regulating intraocular pressure (IOP) is not fully understood.

    Purpose of the Study:

    • To investigate the effect of acetazolamide on IOP in individuals with and without CA-II deficiency.
    • To determine if CA-II is essential for acetazolamide's IOP-lowering effects.

    Main Methods:

    • Two patients with autosomal recessive CA-II deficiency and six healthy control subjects were enrolled.
    • Intravenous acetazolamide (125 mg) was administered to all participants.

    Related Experiment Videos

  • Intraocular pressure was measured at baseline, one hour, and four hours post-administration.

    • Main Results:

    • Control subjects showed a significant decrease in IOP one and four hours after acetazolamide administration (P < .01).
    • Patients with CA-II deficiency exhibited no significant change in IOP at either time point (P > .5).
    • Baseline IOP was higher in CA-II deficient patients compared to controls.

    Conclusions:

    • Carbonic anhydrase II is essential for the intraocular pressure-lowering effect of acetazolamide.
    • This study highlights a potential therapeutic target for managing intraocular pressure.
    • Further research into CA-II's role in ocular physiology is warranted.